Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
Article in Advances in Therapy (January 2023)
The most recent citing publications are shown below. View all 37 publications that cite this research output on Dimensions.
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU
Article in The American Journal of Gastroenterology (December 2022)
Treatment of Perianal Fistulizing Crohn's Disease
Book chapter (September 2022)